GSK: Blenrep Combination Reduced the Risk of Disease Progression or Death by Nearly 50% Versus Standard of Care Combination in Relapsed/refractory Multiple Myeloma
June 04, 2024
June 04, 2024
LONDON, England, June 4 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on June 2, 2024:
GSK plc (LSE/NYSE: GSK) today announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory m . . .
GSK plc (LSE/NYSE: GSK) today announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory m . . .